Abbott received U.S. Food and Drug Administration (FDA) approval for its TactiFlex Duo Ablation Catheter, Sensor Enabled. The device treats atrial fibrillation (AFib), a common irregular heartbeat affecting an estimated 10.5 million people in the U.S. This condition significantly increases the risk of stroke.
The TactiFlex Duo utilizes dual-energy technology, allowing physicians to use pulsed field ablation (PFA), traditional radiofrequency (RF) energy, or both. This innovation enables doctors to tailor treatments to specific patient anatomy during a single procedure.
The device precisely targets heart tissue responsible for abnormal signals while protecting surrounding healthy tissue. This approval expands Abbott's portfolio within the competitive cardiac ablation market.